Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 October 2007 to 31 October 2007 (Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council )
Date: 2007-11-30
Institutions: European Commission
Subjects: EU Member State, market approval, marketing standard, medicinal product, pharmaceutical legislation, veterinary drug, withdrawal from the market

C 288/14

EN

Official Journal of the European Union

30.11.2007

Summary of Community decisions on marketing authorizations in respect of medicinal products
from 1 October 2007 to 31 October 2007

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council (1)
or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council (2))

(2007/C 288/05)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the
decision

Name(s) of the
medicinal product

Holder(s) of the marketing
authorization

Member State concerned

3.10.2007

Aclasta

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex RH12 5AB
United Kingdom

This Decision is addressed to
all Member States

Date of
notification

5.10.2007

23.10.2007

Fentanyl Matrix-
plaster

See Annex I

23.10.2007

Fentanyl TTS

See Annex II

24.10.2007

Xeomin

See Annex III

See Annex II

See Annex III

See Annex I

26.10.2007

26.10.2007

25.10.2007

Date of
notification

3.10.2007

— Revocation of a national marketing authorization

Date of the
decision

Name(s) of the
medicinal product

Holder(s) of the marketing
authorization

Member State concerned

1.10.2007

Veralipride

See Annex IV

See Annex IV

(1) OJ L 311, 28.11.2001, p. 67.
(2) OJ L 311, 28.11.2001, p. 1.

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE
OF ADMINISTRATION, APPLICANTS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER
STATES

ANNEX I

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of administration

Germany

Germany

Germany

Germany

Austria

Austria

Austria

Austria

France

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Fentanyl-ratiopharm 25 µg/h
Matrixpflaster

25 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 50 µg/h
Matrixpflaster

50 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 75 µg/h
Matrixpflaster

75 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 100 µg/h
Matrixpflaster

100 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 25 µg/h
transdermales Matrixpflaster

25 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 50 µg/h
transdermales Matrixpflaster

50 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 75 µg/h
transdermales Matrixpflaster

75 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 100 µg/h
transdermales Matrixpflaster

100 µg/h

Transdermal patch

Transdermal use

Fentanyl ratiopharm 25 µg/h,
dispositif transdermique

25 µg/h

Transdermal patch

Transdermal use

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

.

3
0
1
1
2
0
0
7

.

Content
(Concentration)

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

cm2 which
16,5 mg/30
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

cm2 which
8,25 mg/15
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

cm2 which
16,5 mg/30
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

C

2
8
8
/
1
5

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of administration

France

France

France

The Netherlands

The Netherlands

The Netherlands

The Netherlands

Spain

Spain

Spain

ratiopharm Nederland bv
Ronde Tocht 11
1507 CC Zaandam
Nederland

ratiopharm Nederland bv
Ronde Tocht 11
1507 CC Zaandam
Nederland

ratiopharm Nederland bv
Ronde Tocht 11
1507 CC Zaandam
Nederland

ratiopharm Nederland bv
Ronde Tocht 11
1507 CC Zaandam
Nederland

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Fentanyl ratiopharm 50 µg/h,
dispositif transdermique

50 µg/h

Transdermal patch

Transdermal use

Fentanyl ratiopharm 75 µg/h,
dispositif transdermique

75 µg/h

Transdermal patch

Transdermal use

Fentanyl ratiopharm 100 µg/h,
dispositif transdermique

100 µg/h

Transdermal patch

Transdermal use

Fentanyl ratiopharm 25 µg/uur,
transdermaal
pleister
gebruik

voor

Fentanyl ratiopharm 50 µg/uur,
transdermaal
pleister
gebruik

voor

Fentanyl ratiopharm 75 µg/uur,
transdermaal
pleister
gebruik

voor

Fentanyl ratiopharm 100 µg/
uur, pleister voor transdermaal
gebruik

Fentanilo Matrix ratiopharm 25
microgramos/h parches trans-
dérmicos EFG

Fentanilo Matrix ratiopharm 50
microgramos/h parches trans-
dérmicos EFG

Fentanilo Matrix ratiopharm 75
microgramos/h parches trans-
dérmicos EFG

25 µg/h

Transdermal patch

Transdermal use

50 µg/h

Transdermal patch

Transdermal use

75 µg/h

Transdermal patch

Transdermal use

100 µg/h

Transdermal patch

Transdermal use

25 µg/h

Transdermal patch

Transdermal use

50 µg/h

Transdermal patch

Transdermal use

75 µg/h

Transdermal patch

Transdermal use

Content
(Concentration)

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

cm2 which
16,5 mg/30
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

cm2 which
8,25 mg/15
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

C

2
8
8
/
1
6

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

.

3
0
1
1
2
0
0
7

.

Spain

United Kingdom

United Kingdom

United Kingdom

United Kingdom

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of administration

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

Fentanilo Matrix
ratiopharm
100 microgramos/h parches
transdérmicos EFG

100 µg/h

Transdermal patch

Transdermal use

Content
(Concentration)

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

.

3
0
1
1
2
0
0
7

.

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Telfanyl
Transdermal patch (pending)

25 microgram/hr

25 µg/h

Transdermal patch

Transdermal use

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

E
N

Telfanyl
Transdermal patch (pending)

50 microgram/hr

50 µg/h

Transdermal patch

Transdermal use

Telfanyl
Transdermal patch (pending)

75 microgram/hr

75 µg/h

Transdermal patch

Transdermal use

Telfanyl
Transdermal patch (pending)

100 microgram/hr

100 µg/h

Transdermal patch

Transdermal use

cm2 which
8,25 mg/15
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

C

2
8
8
/
1
7

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE
OF ADMINISTRATION, APPLICANTS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER
STATES

ANNEX II

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of
administration

Content
(Concentration)

Germany

Germany

Germany

Germany

Austria

Austria

Austria

Austria

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Fentanyl-ratiopharm 25 µg/h TTS

25 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 50 µg/h TTS

50 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 75 µg/h TTS

75 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratiopharm 100 µg/h TTS 100 µg/h

Transdermal patch

Transdermal use

Fenturogenox 25 µg/h — transder-
males Matrixpflaster

25 µg/h

Transdermal patch

Transdermal use

Fenturogenox 50 µg/h — transder-
males Matrixpflaster

50 µg/h

Transdermal patch

Transdermal use

Fenturogenox 75 µg/h — transder-
males Matrixpflaster

75 µg/h

Transdermal patch

Transdermal use

Fenturogenox 100 µg/h — trans-
dermales Matrixpflaster

100 µg/h

Transdermal patch

Transdermal use

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

ratiopharm Arzneimittel
Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
A-1140 Wien

C

2
8
8
/
1
8

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

.

3
0
1
1
2
0
0
7

.

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of
administration

Content
(Concentration)

Fentanyl-ratio 25 µg/h, dispositif
transdermique

25 µg/h

Transdermal patch

Transdermal use

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

Fentanyl-ratio 50 µg/h, dispositif
transdermique

50 µg/h

Transdermal patch

Transdermal use

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

E
N

.

3
0
1
1
2
0
0
7

.

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

France

France

France

France

The Netherlands

The Netherlands

The Netherlands

The Netherlands

Spain

Spain

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

Fentanyl-ratio 75 µg/h, dispositif
transdermique

75 µg/h

Transdermal patch

Transdermal use

Fentanyl-ratio 100 µg/h, dispositif
transdermique

100 µg/h

Transdermal patch

Transdermal use

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm 25, pleister
Fentanyl
voor transdermaal gebruik 25 µg/
uur

25 µg/h

Transdermal patch

Transdermal use

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm 50, pleister
Fentanyl
voor transdermaal gebruik 50 µg/
uur

50 µg/h

Transdermal patch

Transdermal use

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm 75, pleister
Fentanyl
voor transdermaal gebruik 75 µg/
uur

75 µg/h

Transdermal patch

Transdermal use

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Fentanyl ratiopharm 100, pleister
voor transdermaal gebruik 100 µg/
uur

100 µg/h

Transdermal patch

Transdermal use

Fentanilo Matrix
microgramos/h parches
micos EFG

ratiomed

25
transdér-

Fentanilo Matrix
microgramos/h parches
micos EFG

ratiomed

50
transdér-

25 µg/h

Transdermal patch

Transdermal use

50 µg/h

Transdermal patch

Transdermal use

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

cm2 which
8,25 mg/15
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

cm2 which
8,25 mg/15
release 50 µg fentanyl per
hour

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

C

2
8
8
/
1
9

Member State

Marketing Authorisation
Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical form

Route of
administration

Content
(Concentration)

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

ratiopharm España, S.A.
Avenida de Burgos 16D
5o Planta
E-28036 Madrid

Spain

Spain

United Kingdom

United Kingdom

United Kingdom

United Kingdom

Fentanilo Matrix
microgramos/h parches
micos EFG

ratiomed

75
transdér-

75 µg/h

Transdermal patch

Transdermal use

Fentanilo Matrix
microgramos/h parches
micos EFG

ratiomed 100
transdér-

100 µg/h

Transdermal patch

Transdermal use

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

ratiopharm GmbH
Graf-Arco-Str. 3
D-89079 Ulm

Ribofen 25 microgram/hr Trans-
dermal patch (pending)

25 µg/h

Transdermal patch

Transdermal use

Ribofen 50 microgram/hr Trans-
dermal patch
(pending)

Ribofen 75 microgram/hr Trans-
dermal patch
(pending)

Ribofen 100 microgram/hr Trans-
dermal patch
(pending)

50 µg/h

Transdermal patch

Transdermal use

75 µg/h

Transdermal patch

Transdermal use

100 µg/h

Transdermal patch

Transdermal use

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

4,125 mg/7,5 cm2 which
release 25 µg fentanyl per
hour

8,25 mg/15
cm2 which
release 50 µg fentanyl per
hour

12,375 mg/22,5 cm2 which
release 75 µg fentanyl per
hour

16,5 mg/30
cm2 which
release 100 µg fentanyl per
hour

C

2
8
8
/
2
0

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

.

3
0
1
1
2
0
0
7

.

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE
OF ADMINISTRATION, APPLICANTS MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

ANNEX III

Member State

Marketing Authorisation Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical Form

Route of administration

Content
(Concentration)

Germany

Denmark

Sweden

Austria

Spain

Finland

France

Italy

Luxembourg

Norway

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

.

3
0
1
1
2
0
0
7

.

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

C

2
8
8
/
2
1

Member State

Marketing Authorisation Holder

Applicant

(Invented)
Name

Strength

Pharmaceutical Form

Route of administration

Content
(Concentration)

Poland

Portugal

United Kingdom

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
D-60318 Frankfurt/Main

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

Xeomin

100 LD50 units

Powder for solution for injec-
tion

For intramuscular
use

C

2
8
8
/
2
2

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
U
n
o
n

i

.

3
0
1
1
2
0
0
7

.

30.11.2007

EN

Official Journal of the European Union

C 288/23

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE
OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

ANNEX IV

Member State

Marketing Authorisation Holder

Invented name

Strength

Pharmaceutical
form

Route of
administration

Belgium

France

Italy

Luxembourg

Portugal

Sanofi-Synthelabo S.A.
Avenue de la Métrologie 5
B-1130 Bruxelles

Sanofi-Aventis France
1-13, Boulevard Anatole France
F-75014 Paris

Sanofi-Synthelabo S.P.A.
via Messina, 38
I-20154 Milano

Sanofi-Synthelabo
Twin Squares, Navona Building
Culliganlaan 1c
B-1831 Diegem

Sanofi-Synthelabo
Produtos Farmacêuticos, S.A. PRT
Empreendimento Lagoas Park
Edifício 7, 2o e 3o
PT-2740-244 Porto Salvo

Agreal

100 mg

Capsule, hard Oral use

Agreal

100 mg

Capsule, hard Oral use

Agradil

100 mg

Capsule, hard Oral use

Agreal

100 mg

Capsule, hard Oral use

Agreal

100 mg

Capsule, hard Oral use